– Innovative R&D Yields Fruitful Results Once Again, Revenue Rises to RMB6.13 Billion- Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 14.0%- New Products Boost Performance Associated Revenue up 39.6% Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovat…